Pyxis Oncology reported net income of -$25.35M for the quarter ended Jun 2026. This income statement covers 23 quarters of results from Sep 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | |||||||||||||||||||||||
| Revenue | 16.15M | 2.82M | 11.04M | ||||||||||||||||||||
| Cost of RevenueCost of Rev | 0.47M | 2.39M | |||||||||||||||||||||
| Gross Profit | 15.67M | 2.82M | 8.65M | ||||||||||||||||||||
| Operating items | |||||||||||||||||||||||
| Research & DevelopmentR&D | 3.21M | 7.85M | 7.23M | 20.07M | 17.17M | 19.03M | 29.85M | 11.90M | 11.39M | 14.69M | 11.61M | 13.03M | 13.95M | 17.74M | 14.02M | 17.04M | 17.13M | 17.81M | 21.71M | 16.06M | |||
| Selling, General & AdministrativeSG&A | 2.74M | 3.77M | 9.20M | 11.32M | 8.56M | 9.36M | 8.12M | 9.05M | 6.73M | 10.67M | 6.16M | 8.25M | 6.08M | 6.01M | 5.08M | 5.87M | 5.44M | 5.65M | 5.23M | 9.93M | |||
| Other Operating ExpensesOther Opex | 0.47M | 20.96M | 2.39M | ||||||||||||||||||||
| Operating ExpensesOpex | 5.94M | 11.62M | 16.43M | 31.39M | 25.73M | 28.39M | 37.97M | 20.95M | 18.12M | 25.35M | 17.77M | 21.75M | 20.03M | 23.75M | 40.07M | 22.91M | 22.57M | 23.46M | 29.33M | 25.99M | |||
| Operating IncomeOp. Inc | -5.94M | -11.62M | -16.43M | -31.39M | -25.73M | -28.39M | -37.97M | -20.95M | -18.12M | -25.35M | -17.77M | -5.61M | -20.03M | -23.75M | -40.07M | -22.91M | -19.75M | -23.46M | -18.30M | -25.99M | |||
| EBIT | -5.94M | -11.62M | -16.43M | -31.39M | -25.73M | -28.39M | -37.97M | -20.95M | -18.12M | -25.35M | -17.77M | -5.61M | -20.03M | -23.75M | -40.07M | -22.91M | -19.75M | -23.46M | -18.30M | -25.99M | |||
| Non-operating items | |||||||||||||||||||||||
| Non Operating Investment IncomeNon-Op. Investment Inc. | 0.70M | -0.78M | -0.02M | 0.17M | -0.12M | -0.04M | 0.45M | -0.18M | -0.12M | -0.05M | 0.07M | -0.02M | -0.00M | ||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.01M | 0.01M | 0.01M | 0.01M | 0.16M | 0.72M | 1.87M | 1.67M | 1.66M | 1.71M | 1.59M | 1.60M | 2.02M | 1.85M | 1.62M | 1.24M | 1.00M | 0.80M | 0.60M | 0.30M | |||
| Other Non Operating IncomeOther Non Op Inc. | -2.16M | -2.56M | -0.41M | ||||||||||||||||||||
| Non Operating IncomeNon Op. Inc. | -1.97M | -2.55M | -0.40M | 0.01M | 0.16M | 0.72M | 1.87M | 1.71M | 2.22M | 2.31M | 2.17M | 2.35M | 2.73M | 2.55M | 2.33M | 1.76M | 1.68M | 1.46M | 1.29M | 0.64M | |||
| Net income details | |||||||||||||||||||||||
| EBT | -5.93M | -11.62M | -16.42M | -31.38M | -25.56M | -27.67M | -36.10M | -19.28M | -16.46M | -23.65M | -16.17M | -4.00M | -17.30M | -21.20M | -37.73M | -21.67M | -18.07M | -22.00M | -17.00M | -25.35M | |||
| Tax ProvisionsTaxes | -2.16M | 0.28M | -16.70M | ||||||||||||||||||||
| Profit After TaxPAT | -8.15M | -14.18M | -16.85M | -31.38M | -25.56M | -27.67M | -36.10M | -19.24M | -16.68M | -23.07M | -15.50M | -3.26M | -17.34M | -21.20M | -35.53M | -21.16M | -18.41M | -22.00M | -18.12M | -25.35M | |||
| Equity Income | -0.23M | ||||||||||||||||||||||
| Income from Non-Controlling InterestsInc. Minority | 0.04M | 0.60M | 0.60M | 0.60M | 0.80M | 0.71M | 0.70M | 0.71M | 0.52M | 0.70M | 0.70M | 0.70M | 0.40M | ||||||||||
| Income from Continuing OperationsIncome (Continuing) | -5.93M | -11.62M | -16.42M | -31.38M | -25.56M | -27.67M | -36.10M | -19.28M | -16.46M | -23.65M | -16.17M | -4.00M | -17.30M | -21.20M | -35.57M | -21.67M | -18.35M | -22.00M | -0.30M | -25.35M | |||
| Consolidated Net IncomeConsol Net Inc. | -5.93M | -11.62M | -16.42M | -31.38M | -25.56M | -27.67M | -36.10M | -19.28M | -16.46M | -23.65M | -16.17M | -4.00M | -17.30M | -21.20M | -35.57M | -21.67M | -18.35M | -22.00M | -0.30M | -25.35M | |||
| Income towards Parent CompanyParent Net Inc | -5.93M | -11.62M | -16.42M | -31.38M | -25.56M | -27.67M | -36.10M | -19.28M | -16.46M | -23.65M | -16.17M | -4.00M | -17.30M | -21.20M | -35.57M | -21.67M | -18.35M | -22.00M | -0.30M | -25.35M | |||
| Net Income towards Common StockholdersNet Income | -5.93M | -11.62M | -16.42M | -31.38M | -25.56M | -27.67M | -36.10M | -19.28M | -16.46M | -23.65M | -16.17M | -4.00M | -17.30M | -21.20M | -35.57M | -21.67M | -18.35M | -22.00M | -0.30M | -25.35M | |||
| Additional items | |||||||||||||||||||||||
| EPS (Basic) | -4.03 | -7.34 | -1.93 | -0.97 | -0.79 | -0.85 | -1.09 | -0.55 | -0.43 | -0.57 | -0.41 | -0.08 | -0.29 | -0.35 | -0.61 | -0.36 | -0.30 | -0.35 | 0.00 | -0.40 | |||
| EPS (Diluted) | -4.03 | -7.34 | -1.93 | -0.97 | -0.79 | -0.85 | -1.09 | -0.55 | -0.43 | -0.57 | -0.41 | -0.08 | -0.29 | -0.35 | -0.61 | -0.36 | -0.30 | -0.35 | 0.00 | -0.40 | |||
| Shares Outstanding | 1.47M | 1.58M | 8.49M | 32.32M | 32.45M | 32.56M | 33.03M | 35.35M | 38.39M | 41.33M | 39.90M | 51.29M | 60.50M | 60.72M | 58.45M | 61.05M | 61.92M | 62.56M | 62.14M | 63.99M | |||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 1.47M | 1.58M | 8.49M | 32.32M | 32.45M | 32.56M | 33.03M | 35.35M | 38.39M | 41.33M | 39.90M | 51.29M | 60.50M | 60.72M | 58.45M | 61.05M | 61.92M | 62.56M | 62.14M | 63.99M | |||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 1.52M | 1.58M | 8.49M | 32.37M | 32.48M | 32.59M | 34.96M | 36.92M | 39.38M | 44.29M | 44.75M | 58.80M | 58.91M | 59.45M | 59.97M | 61.63M | 62.02M | 62.15M | 62.69M | 63.43M | |||
| EBITDA | -5.94M | -11.62M | -16.43M | -31.39M | -25.73M | -28.39M | -37.97M | -20.95M | -18.12M | -25.35M | -17.77M | -5.61M | -20.03M | -23.75M | -40.07M | -22.91M | -19.75M | -23.46M | -18.30M | -25.99M | |||
| Tax Rate | 5.73% | -1.57% | 98.22% |